Cellectar Biosciences to Present Early CLOVER WaM Data at ASCO 2026 — Cellectar Biosciences, Inc.

Event summary

Cellectar Biosciences' abstract on iopofosine I-131 in Waldenström macroglobulinemia accepted for ASCO 2026 poster presentation.
Data subset focuses on relapsed/refractory WM patients post-BTK inhibitor failure, a population with no FDA-approved therapies.
Poster presentation scheduled for June 1, 2026, featuring COO Jarrod Longcor as presenter.
Company highlights iopofosine's potential as differentiated therapy in second-line treatment setting.

The big picture

The presentation represents an early validation opportunity for Cellectar's targeted radiotherapeutic approach in a rare cancer niche with significant unmet need. With over 1,000 US patients having exhausted standard options by third line, successful differentiation could position iopofosine as the first FDA-approved alternative to continuous BTK inhibitor therapy.

What we're watching

Regulatory Pathway: Whether ASCO data presentation will accelerate FDA engagement for iopofosine's post-BTK inhibitor indication.
Clinical Validation: The extent to which poster data demonstrates differentiated efficacy in heavily pretreated WM patients.
Market Positioning: How Cellectar positions iopofosine against non-FDA approved salvage therapies dominating current treatment landscape.